YURIKO FUKUTA to Humans
This is a "connection" page, showing publications YURIKO FUKUTA has written about Humans.
Connection Strength
0.207
-
Role of Wound Care in Management of Severe Verrucous Papular Lesions Due to Mpox Infection: A Case Report. Adv Skin Wound Care. 2025 Sep 01; 38(8):E69-E72.
Score: 0.025
-
Fungal Osteomyelitis of a Diabetic Foot Infection Caused by Trichosporon asahii: A Case Report. Adv Skin Wound Care. 2024 Nov-Dec 01; 37(11&12):1-4.
Score: 0.024
-
Infectious Diseases Management in Wound Care Settings: Common Causative Organisms and Frequently Prescribed Antibiotics. Adv Skin Wound Care. 2022 Oct 01; 35(10):535-543.
Score: 0.021
-
Joint Initiative Between Infectious Diseases and Podiatry in Outpatient Settings Improves Outcomes and Adherence to Treatment. Adv Skin Wound Care. 2021 Apr 01; 34(4):210-213.
Score: 0.019
-
Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am J Infect Control. 2013 Dec; 41(12):1249-52.
Score: 0.011
-
Infections in psychiatric facilities, with an emphasis on outbreaks. Infect Control Hosp Epidemiol. 2013 Jan; 34(1):80-8.
Score: 0.011
-
Identifying the risk factors for hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infection among patients colonized with MRSA on admission. Infect Control Hosp Epidemiol. 2012 Dec; 33(12):1219-25.
Score: 0.011
-
Lack of seasonality in the occurrence of multidrug-resistant Acinectobacter baumannii complex. Infect Control Hosp Epidemiol. 2012 Oct; 33(10):1051-2.
Score: 0.010
-
Legionella micdadei prosthetic valve endocarditis complicated by brain abscess: case report and review of the literature. Scand J Infect Dis. 2012 Jun; 44(6):414-8.
Score: 0.010
-
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. JCI Insight. 2024 Mar 14; 9(8).
Score: 0.006
-
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial. Microbiol Spectr. 2024 Jan 11; 12(1):e0328623.
Score: 0.006
-
Early antibody treatment, inflammation, and risk of post-COVID conditions. mBio. 2023 10 31; 14(5):e0061823.
Score: 0.006
-
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study. Lancet Microbe. 2023 09; 4(9):e692-e703.
Score: 0.006
-
Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials. Transfusion. 2023 09; 63(9):1639-1648.
Score: 0.006
-
Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials. Clin Infect Dis. 2023 06 16; 76(12):2077-2086.
Score: 0.005
-
Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial. J Infect Dis. 2023 05 29; 227(11):1266-1273.
Score: 0.005
-
Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. Clin Infect Dis. 2023 02 08; 76(3):e477-e486.
Score: 0.005
-
Undetectable JC virus CSF PCR in patients with JC virus-induced progressive multifocal leukoencephalopathy. J Neurovirol. 2023 02; 29(1):94-99.
Score: 0.005
-
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Adv. 2022 06 28; 6(12):3678-3683.
Score: 0.005
-
How do I implement an outpatient program for the administration of convalescent plasma for COVID-19? Transfusion. 2022 05; 62(5):933-941.
Score: 0.005
-
Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N Engl J Med. 2022 05 05; 386(18):1700-1711.
Score: 0.005